Role of Ga-68 Somatostatin Receptor PET/CT in the Assessment of Response to Radiofrequency Ablation in Hepatic Metastases of Neuroendocrine Tumors Abstract #563

Introduction: Patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) present frequently with hepatic metastases. Radiofrequency ablation (RFA) is an important local ablative treatment for hepatic metastases.
Aim(s): To evaluate the role of Ga-68 somatostatin receptor PET/CT (SSTR PET/CT) in the assessment of response to RFA in hepatic metastases of NET in comparison with the other radiological imaging modalities.
Materials and methods: Ten patients of known GEP-NET underwent RFA (in total of 17 segments) for hepatic metastases. All patients had undergone SSTR PET/CT using Ga-68 DOTATOC, 4-phase CT, MRI and USG before, and 3-6 months after RFA.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Richard P Baum

To read results and conclusion, please login ...

Further abstracts you may be interested in

#26 Molecular imaging of gastroenteropancreatic neuroendocrine tumours with Ga-68 DOTANOC PET/CT and correlation with an immunhistochemical quantification of somatostatin receptors using novel monoclonal and polyclonal antibodies
Introduction: Receptor PET/CT with somatostatin analogues marked with Gallium-68 (SMS-R-PET/CT) is currently the golden standard in diagnosing gastroenteropancreatic neuroendocrine tumors (GEP-NET), which are known for an overexpression of somatostatin receptors (SSTRs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#169 Radio guided surgery in neuroendocrine tumours using 68Ga-labeled somatostatin analogs – a pilot study.
Introduction: Radioguided surgery (RGS) is an intraoperative localizing technique for the detection of cancer tissue using tumor-specific radionuclides.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#302 Monoclonal Antibodies Against the Human Somatostatin Receptor Subtypes 1-5: Characterization and Immunohistochemical Application in Gastrointestinal Neuroendocrine Tumors
Introduction: A lack of well-characterized somatostatin receptor (sstr)-specific antibodies has hampered development of routine sstr expression profiles that may be useful in the treatment of NET patients (pts).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Chiara Lambertini
#567 Efficacy of Combined Peptide Receptor Radionuclide Therapy and Radiofrequency Ablation for the Management of Hepatic Metastases of Neuroendocrine Tumors
Introduction: Hepatic metastases significantly affect the overall prognosis and quality of life in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET). Radiofrequency ablation (RFA) is one of the important local ablative strategies for hepatic metastases. Peptide receptor radionuclide therapy (PRRNT) is a well-established therapeutic modality for metastatic NET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Richard P Baum
#571 Safety and Efficacy of Peptide Receptor Radionuclide Therapy after Liver Transplantation in Metastatic Neuroendocrine Tumors
Introduction: Liver transplantation is an important option for patients of neuroendocrine tumors (NET) with metastases limited to the liver. Peptide receptor radionuclide therapy (PRRNT) is effective in the management of metastatic NET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Richard P Baum